EPS for Genocea Biosciences, Inc. (GNCA) Expected At $-0.09

Genocea Biosciences, Inc. (NASDAQ:GNCA) Logo

Analysts expect Genocea Biosciences, Inc. (NASDAQ:GNCA) to report $-0.09 EPS on May, 9.They anticipate $0.05 EPS change or 35.71 % from last quarter’s $-0.14 EPS. After having $-0.13 EPS previously, Genocea Biosciences, Inc.’s analysts see -30.77 % EPS growth. The stock increased 0.86% or $0.006 during the last trading session, reaching $0.706. About 155,874 shares traded. Genocea Biosciences, Inc. (NASDAQ:GNCA) has declined 21.29% since April 16, 2018 and is downtrending. It has underperformed by 25.66% the S&P500.

Genocea Biosciences, Inc. (NASDAQ:GNCA) Ratings Coverage

Among 2 analysts covering Genocea Biosciences (NASDAQ:GNCA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Genocea Biosciences had 4 analyst reports since November 27, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, February 28 by H.C. Wainwright. The rating was maintained by Needham on Friday, March 1 with “Buy”. The stock of Genocea Biosciences, Inc. (NASDAQ:GNCA) earned “Buy” rating by H.C. Wainwright on Tuesday, November 27.

Genocea Biosciences, Inc., a biopharmaceutical company, engages in developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. The company has market cap of $79.35 million. The firm uses AnTigen Lead Acquisition System , its proprietary discovery platform to build a pipeline of immunotherapies and its first neoantigen cancer vaccine. It currently has negative earnings. The Company’s lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase 2 trial for the treatment of genital herpes infections.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More notable recent Genocea Biosciences, Inc. (NASDAQ:GNCA) news were published by: Globenewswire.com which released: “Genocea Doses First Patients and Completes Enrollment in Part A of Phase 1/2a Clinical Trial for Neoantigen Vaccine Candidate GEN-009 – GlobeNewswire” on January 02, 2019, also Nasdaq.com with their article: “Genocea to Present at 18th Annual Needham Healthcare Conference – Nasdaq” published on April 03, 2019, Globenewswire.com published: “Genocea to Present at Two October Investor Conferences – GlobeNewswire” on September 24, 2018. More interesting news about Genocea Biosciences, Inc. (NASDAQ:GNCA) were released by: Globenewswire.com and their article: “Genocea Appoints Girish Aakalu, Ph.D., Chief Business Officer – GlobeNewswire” published on December 10, 2018 as well as Globenewswire.com‘s news article titled: “Genocea Reports Third Quarter 2018 Financial and Operating Results – GlobeNewswire” with publication date: November 01, 2018.

Genocea Biosciences, Inc. (NASDAQ:GNCA) Ratings Chart